Dear Aspirants
IASbhai Current Affairs News Analysis | Prelims & Mains 2020 is an initiative to dilute major articles from leading Newspapers in India which are most relevant to UPSC preparation –‘THE HINDU, LIVEMINT , INDIAN EXPRESS’ and help millions of readers who find difficulty in answer writing and making notes everyday. Hence we choose articles on daily basis and analyse them with respect to UPSC PRELIMS 2020.

“Don’t raise your voice, improve your argument.” –Anonymous


ORANGE COLOUR: Important for Prelims.

RED COLOUR: Important for Mains.


BLUE COLOUR : Important Links/Survey.

PINK COLOUR: Reports/Themes/Summits.

5th Sep Current Affairs News Analysis | Prelims & Mains 2020

Today's Must Read Articles : Today's Must Read Articles :

KIRAN Helpline


Shri Thaawarchand Gehlot to Launch 24×7 Toll-Free Mental Health Rehabilitation Helpline (1800-599-0019) ‘KIRAN’ On 7th September, 2020

      WHY IN NEWS:

Union Minister for Social Justice and Empowerment will launch the “24×7 Toll-Free Mental Health Rehabilitation Helpline “KIRAN” (1800-500-0019)” through virtual mode

MINISTRY? :-Ministry of Social Justice & Empowerment


This assumes great significance in view of the growing incidence of Mental Illness, particularly in the wake of COVID-19 Pandemic.


  • This Helpline has been developed by the Department of Empowerment of Persons with Disabilities (DEPwD), Ministry of Social Justice & Empowerment.


  • The aim is to provide relief and support to persons with Mental Illness.

This helpline will offer mental health rehabilitation services with the objective of early screening, first-aid and psychological support.

  • The focus will be on distress management, mental well-being, promoting positive behaviors, psychological crisis management etc.

      IASbhai WINDUP: 

It will function as a lifeline to provide 1st stage advice, counseling and reference to individuals, families, NGOs, Parent Associations, Professional Associations, Rehabilitation Institutes, Hospitals or anyone in need of support across the country.

     SOURCES: PIB | 5th Sep Current Affairs News Analysis

Kaziranga set to be expanded


Kaziranga set to be expanded by 3,053 hectares

      WHY IN NEWS:

Assam govt. approves addition of areas straddling Nagaon and Sonitpur

SYLLABUS COVERED: GS 3: National Parks


The new areas include regions that are vulnerable to encroachment.


  • The Assam government has approved the addition of 30.53 sq. km ( 3,053 hectares) to the 884 sq. km Kaziranga National Park.
  • The additional areas straddling two districts — Nagaon and Sonitpur — would make the Kaziranga National Park and Tiger Reserve (KNPTR) grow to 1085.53 sq km.
  • The core area of the KNPTR is 430 sq km.


  • The additions include encroachment-evicted areas and suitable wildlife habitat on river islands (sandbars) that are vulnerable to encroachment.
  • It is a move to consolidate the wildlife areas anticipating better wildlife conservation and reduction in human-wildlife negative interactions in the future.

Additions of habitat corridors and would help provide connectivity to Orang and Nameri National Parks across river Brahmaputra. 

  • The hills of Karbi Anglong to the south of the park, where the rhino, tiger, deer and other animals take refuge during the floods.

      IASbhai WINDUP: 

Wildlife activists appreciated the expansion but pointed out that the rhino habitat is yet to be handed over possession of 1,461.59 hectares of land .

     SOURCES: PIB | 5th Sep Current Affairs News Analysis

Russia’s COVID-19 vaccine is safe


Russia’s COVID-19 vaccine is safe

      WHY IN NEWS:

It generated a strong immune response and didn’t produce serious adverse reactions during the trial’

SYLLABUS COVERED: GS 3:Health:Diseases


Promising results: A staffer at Gamaleya Research Institute displaying a vaccine vial.

  • The two-shot vaccine being developed by Russia’s Gamaleya Research Institute generated a strong immune response.
  • It didn’t produce serious adverse reactions in the 76 volunteers who were inoculated in a trial.-Lancet
  • This is the first time that details of the early human studies — or Phase-1/2 trials, to check the vaccine’s safety and ability to generate an immune response — of the vaccines have been reported in a peer-reviewed journal.


The vaccine consists of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector.

  • Both carry the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S).
  • Adenoviruses commonly affect humans and primates and have emerged as a sought-after platform to develop a vaccine against COVID-19.
  • The ChAdOx1 vaccine candidate developed by Oxford University is based on a chimpanzee adenovirus vector platform .
  • Beijing Institute of Biotechnology and CanSino Biologics Inc. of China too are developing a vaccine on an adenovirus platform.


  • The vaccines were given to the selected volunteers 21 days apart.
  • The spacing meant to generate a boosted response .

It checked for whether it induced protective antibodies as well as if it managed to stimulate the body’s cells into producing a class of cells that can destroy viral cells, a process known as a ‘humoral response.’

  • However, between 28% and 50% of the volunteers reported pain at injection site, hyperthermia, headache, asthenia and muscle and joint pain.
  • “Most adverse events were mild and no serious adverse events were detected,”.

      IASbhai WINDUP: 

  • Russian scientists said they had begun Phase-3 trials of their vaccine in 40,000 volunteers, results of which are likely to be publicly known by November.
  • So far, adenoviral vector vaccines have never been tested in commercial human vaccines except for a rabies vaccine.
     SOURCES:DownToEarth | 5th Sep Current Affairs News Analysis

DISCOVER MORE : Important Daily Current Affairs for UPSC PRELIMS 2020

If you liked this article, then please subscribe to our YouTube Channel for Daily Current Affairs , Editorial Analysis & Answer writing video tutorials. You can also find us on Twitter and Facebook.

You May Also Like